La cadena de opciones muestra datos clave de las opciones de acciones de Upwork a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Upwork..

Upwork (NASDAQ:UPWK) Bolsa, Cadena de Opciones

Upwork

Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.

Upwork Inc

UPWORK ORD

<p>TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect TELUS to report an <strong>earnings per share</strong> (EPS) of $0.18.</p>
<p>The market awaits TELUS's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at TELUS's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.16</td>
<td>0.170</td>
<td>0.170</td>
<td>0.240</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.192</td>
<td>0.176</td>
<td>0.186</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995313_0.png" alt="eps graph" /></p>
<h3>TELUS Share Price Analysis</h3>
<p>Shares of TELUS were trading at $15.11 as of November 06. Over the last 52-week period, shares are down 12.1%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TU/earnings"><strong>To track all earnings releases for TELUS visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Uncovering Potential: TELUS's Earnings Preview

<p>5 analysts have expressed a variety of opinions on Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $65.4, accompanied by a high estimate of $77.00 and a low estimate of $55.00. Highlighting a 1.51% decrease, the current average has fallen from the previous average price target of $66.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995312_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ionis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ionis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Ionis Pharmaceuticals Better</h2>
<p>Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.</p>
<h3>Ionis Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ionis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>19.55%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Ionis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-29.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-23.66%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-2.43%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>5.47</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

IONS

A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts

<p>9 analysts have expressed a variety of opinions on Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.89, along with a high estimate of $95.00 and a low estimate of $64.00. Observing a 10.81% increase, the current average has risen from the previous average price target of $73.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995304_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Johnson Controls Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson Controls Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson Controls Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Johnson Controls Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Johnson Controls Intl's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Johnson Controls Intl analyst ratings.</strong></a></p>
<h2>Get to Know Johnson Controls Intl Better</h2>
<p>Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.</p>
<h3>Johnson Controls Intl's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Johnson Controls Intl's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>1.37%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Johnson Controls Intl's net margin is impressive, surpassing industry averages. With a net margin of <strong>13.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>6.17%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Johnson Controls Intl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Johnson Controls Intl's debt-to-equity ratio is below the industry average. With a ratio of <b>0.65</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Johnson Controls Intl Through 9 Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Hims &amp; Hers Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 3 are puts, totaling $130,350, and 7 are calls, amounting to $304,590.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $35.0 for Hims &amp; Hers Health during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Hims &amp; Hers Health stands at 1738.22, with a total volume reaching 1,550.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hims &amp; Hers Health, situated within the strike price corridor from $15.0 to $35.0, throughout the last 30 days.</p>
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995296_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.0</td>
<td>$1.85</td>
<td>$1.95</td>
<td>$25.00</td>
<td>$58.5K</td>
<td>146</td>
<td align="right">303</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$8.4</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$20.00</td>
<td>$58.1K</td>
<td>3.5K</td>
<td align="right">172</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$24.00</td>
<td>$46.6K</td>
<td>124</td>
<td align="right">81</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.9</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$24.00</td>
<td>$45.8K</td>
<td>124</td>
<td align="right">160</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$11.5</td>
<td>$11.3</td>
<td>$11.38</td>
<td>$15.00</td>
<td>$45.5K</td>
<td>907</td>
<td align="right">48</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.</p>
<p>In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Trading volume stands at 4,521,358, with HIMS's price up by 0.17%, positioned at $23.46.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 109 days.</li>
</ul>
<h3>Professional Analyst Ratings for Hims &amp; Hers Health</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $24.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Neutral, setting a price target of $21.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Hims &amp; Hers Health, targeting a price of $25.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $23.<br />
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Hold rating for Hims &amp; Hers Health, targeting a price of $27.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Hims &amp; Hers Health, which currently sits at a price target of $28. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Smart Money Is Betting Big In HIMS Options

<p>U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.</p>
<p>Shares of <strong>HubSpot, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results and issued FY24 <a href="https://www.benzinga.com/news/earnings/24/11/41790530/hubspot-shares-climb-after-strong-q3-results-eps-beat-revenues-beat">guidance above estimates</a>.</p>
<p>HubSpot reported quarterly earnings of $2.22 per share, which beat the analyst consensus estimate of $1.91. Quarterly revenue clocked in at $669.7 million which beat the analyst consensus estimate of $646.9 million and is an increase over sales of $557.55 million from the same period last year.</p>
<p>HubSpot shares jumped 7.9% to $645.11 on Thursday.</p>
<p>Here are some other big stocks recording gains in today's session.</p>
<ul>
<li><strong>AppLovin Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares jumped 47% to $247.63 after the company reported better-than-expected third-quarter financial results.</li>
<li><strong>Dutch Bros In</strong>c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) surged 39% to $48.57 following third-quarter earnings.</li>
<li><strong>Emergent BioSolutions Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 34.8% to $12.40 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li><strong>FARO Technologies, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) gained 32.8% to $25.07 following third-quarter results.</li>
<li><strong>Under Armour, In</strong>c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) gained 32.7% to $11.61 after the company reported better-than-expected quarterly EPS and sales.</li>
<li><strong>Lyft, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 28.2% to $18.46 after the company reported better-than-expected quarterly financial results.</li>
<li><strong>Freshworks Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) jumped 26.2% to $16.51 following upbeat quarterly results.</li>
<li><strong>Wolverine World Wide, In</strong>c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) jumped 26.2% to $20.25 following strong quarterly results.</li>
<li><strong>Zillow Group, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 22.4% to $68.66 after the company reported better-than-expected quarterly financial results.</li>
<li><strong>IonQ, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) rose 21.4% to $19.98 following third-quarter results.</li>
<li><strong>Clearwater Analytics Holdings, In</strong>c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) gained 20.9% to $34.56 following better-than-expected quarterly earnings.</li>
<li><strong>Hanesbrands Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 17% to $8.32 following upbeat earnings.</li>
<li><strong>e.l.f. Beauty, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) rose 16% to $120.80 following stronger-than-expected quarterly earnings.</li>
<li><strong>Guardant Health, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) gained 15.5% to $29.20 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li><strong>Kyndryl Holdings, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) gained 15.3% to $27.81 after reporting upbeat quarterly results.</li>
<li><strong>Warner Bros. Discovery, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>) surged 14.7% to $9.61 following third-quarter earnings.</li>
<li><strong>EPAM Systems, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) gained 13.7% to $230.60 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li><strong>McKesson Corporatio</strong>n (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) rose 10.4% to $606.61 as the company reported better-than-expected second-quarter financial results.</li>
<li><strong>Mobileye Global Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 9.7% to $16.95.</li>
<li><strong>The Estée Lauder Companies Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 6.6% to $67.46.</li>
<li><strong>Arm Holdings plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NYSE">ARM</a>) gained 5.4% to $152.43 following second-quarter results.</li>
</ul>
<p><strong>Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp"> </a></strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></strong></li>
</ul>


News

Intraday Update

Movers

BROS

CWAN

EPAM

FARO

FRSH

HUBS

IONQ

LYFT

MBLY

HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday

<p>UBS  analyst Kevin Caliendo   maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $60 to $62.</p>


Price Target

UBS Maintains Neutral on CVS Health, Raises Price Target to $62

<p>Throughout the last three months, 15 analysts have evaluated T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $111.87, a high estimate of $129.00, and a low estimate of $99.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.6%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995291_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of T. Rowe Price Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$116.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$115.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$129.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$101.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$112.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$102.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$108.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Announces</td>
<td>Underweight</td>
<td>$99.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$113.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to T. Rowe Price Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of T. Rowe Price Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of T. Rowe Price Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into T. Rowe Price Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TROW/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on T. Rowe Price Gr analyst ratings.</strong></a></p>
<h2>Delving into T. Rowe Price Gr's Background</h2>
<p>T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of August 2024, the firm had $1.612 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.</p>
<h3>Unraveling the Financial Story of T. Rowe Price Gr</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining T. Rowe Price Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.88%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> T. Rowe Price Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>32.9%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> T. Rowe Price Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.82%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> T. Rowe Price Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.38%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, T. Rowe Price Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TROW

Key Takeaways From T. Rowe Price Gr Analyst Ratings

<p>Financial giants have made a conspicuous bullish move on RH. Our analysis of options history for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 55% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $221,337, and 4 were calls, valued at $328,450.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $380.0 for RH over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for RH options trades today is 163.0 with a total volume of 210.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for RH's big money trades within a strike price range of $300.0 to $380.0 over the last 30 days.</p>
<h3>RH Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995290_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$55.7</td>
<td>$54.6</td>
<td>$55.2</td>
<td>$300.00</td>
<td>$176.6K</td>
<td align="right">448</td>
<td align="right">36</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$20.4</td>
<td>$19.3</td>
<td>$19.3</td>
<td>$340.00</td>
<td>$77.2K</td>
<td align="right">0</td>
<td align="right">40</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$20.0</td>
<td>$18.6</td>
<td>$18.6</td>
<td>$330.00</td>
<td>$74.4K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$94.2</td>
<td>$92.0</td>
<td>$92.0</td>
<td>$380.00</td>
<td>$46.0K</td>
<td align="right">31</td>
<td align="right">5</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$41.4</td>
<td>$39.7</td>
<td>$40.31</td>
<td>$320.00</td>
<td>$40.3K</td>
<td align="right">721</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About RH</h3>
<p>RH is a luxury furniture and lifestyle retailer operating in the $134 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 18 restaurant locations. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade by expanding abroad, with its World of RH digital platform (highlighting offerings outside of home furnishings), and with offerings in color, bespoke furniture, architecture, media, and more.</p>
<p>Having examined the options trading patterns of RH, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of RH</h3>
<ul>
<li>With a trading volume of 196,508, the price of RH is up by 4.59%, reaching $338.49.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 28 days from now.</li>
</ul>
<h3>What Analysts Are Saying About RH</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $430.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Wedbush upgrades its rating to Outperform with a revised price target of $430. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest RH options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With RH

WIIM

LILA

LILAB

LILAK

Liberty Latin America shares are trading lower after the company reported worse-than-expected Q3 revenue results.

<p>Financial giants have made a conspicuous bullish move on Wells Fargo. Our analysis of options history for Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 55% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $67,027, and 7 were calls, valued at $331,635.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $52.5 to $75.0 for Wells Fargo during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Wells Fargo options trades today is 8195.5 with a total volume of 2,971.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Wells Fargo's big money trades within a strike price range of $52.5 to $75.0 over the last 30 days.</p>
<h3>Wells Fargo Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995285_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$18.75</td>
<td>$18.5</td>
<td>$18.5</td>
<td>$52.50</td>
<td>$123.9K</td>
<td>13.0K</td>
<td align="right">68</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$6.35</td>
<td>$6.5</td>
<td>$65.00</td>
<td>$48.7K</td>
<td>13.7K</td>
<td align="right">135</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.65</td>
<td>$12.45</td>
<td>$12.5</td>
<td>$60.00</td>
<td>$37.5K</td>
<td>10.8K</td>
<td align="right">49</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$18.75</td>
<td>$18.65</td>
<td>$18.65</td>
<td>$52.50</td>
<td>$37.3K</td>
<td>2.1K</td>
<td align="right">20</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.14</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$70.00</td>
<td>$35.9K</td>
<td>2.6K</td>
<td align="right">542</td>
</tr>
</tbody>
</table>
</p>
<h3>About Wells Fargo</h3>
<p>Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.</p>
<h3>Where Is Wells Fargo Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,156,095, with WFC's price down by -2.5%, positioned at $70.66.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What The Experts Say On Wells Fargo</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $66.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Wells Fargo, targeting a price of $71.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $61.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Wells Fargo, maintaining a target price of $77.<br />
&#x2A; Maintaining their stance, an analyst from Compass Point continues to hold a Neutral rating for Wells Fargo, targeting a price of $60.<br />
&#x2A; An analyst from Phillip Securities upgraded its action to Accumulate with a price target of $65. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wells Fargo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Wells Fargo Unusual Options Activity For November 07

<p>Across the recent three months, 4 analysts have shared their insights on MasterCraft Boat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated MasterCraft Boat Hldgs and provided 12-month price targets. The average target is $19.0, accompanied by a high estimate of $22.00 and a low estimate of $15.00. Marking an increase of 5.56%, the current average surpasses the previous average price target of $18.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995283_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of MasterCraft Boat Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brandon Rolle</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MasterCraft Boat Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MasterCraft Boat Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of MasterCraft Boat Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MasterCraft Boat Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MCFT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MasterCraft Boat Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind MasterCraft Boat Hldgs</h2>
<p>MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.</p>
<h3>MasterCraft Boat Hldgs's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> MasterCraft Boat Hldgs's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-59.67%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> MasterCraft Boat Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-11.96%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> MasterCraft Boat Hldgs's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-4.22%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> MasterCraft Boat Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.44%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.27</strong>, MasterCraft Boat Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MCFT

Where MasterCraft Boat Hldgs Stands With Analysts

<p>Susquehanna  analyst Shyam Patil   maintains trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) with a Neutral and lowers the price target from $2.25 to $1.75.</p>


TRVG

Susquehanna Maintains Neutral on trivago, Lowers Price Target to $1.75

<p>During the last three months, 12 analysts shared their evaluations of Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $85.92, a high estimate of $91.00, and a low estimate of $75.00. This current average has increased by 1.96% from the previous average price target of $84.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995275_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Voya Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Voya Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Voya Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Voya Financial's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Voya Financial's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VOYA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Voya Financial analyst ratings.</strong></a></p>
<h2>Get to Know Voya Financial Better</h2>
<p>Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.</p>
<h3>Key Indicators: Voya Financial's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Voya Financial's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-3.01%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Voya Financial's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.08%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.24%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Voya Financial's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.06%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Voya Financial's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.53</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VOYA

The Analyst Landscape: 12 Takes On Voya Financial

<p>In the last three months, 6 analysts have published ratings on Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.5, a high estimate of $36.00, and a low estimate of $27.00. Observing a 15.26% increase, the current average has risen from the previous average price target of $27.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995268_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Waystar Holding. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Waystar Holding. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Waystar Holding compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waystar Holding's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Waystar Holding analyst ratings.</strong></a></p>
<h2>Delving into Waystar Holding's Background</h2>
<p>Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other US Territories.</p>
<h3>Key Indicators: Waystar Holding's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Waystar Holding's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>19.68%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-11.8%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Waystar Holding's ROE excels beyond industry benchmarks, reaching <strong>-1.11%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Waystar Holding's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-0.61%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Waystar Holding's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.47</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Waystar Holding Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<p>Susquehanna  analyst Bascome Majors   maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Neutral and lowers the price target from $29 to $26.</p>


SNDR

Susquehanna Maintains Neutral on Schneider National, Lowers Price Target to $26

Clearwater Analytics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance. JP Morgan upgraded the stock from Neutral to Overweight and multiple firms raised their respective price targets.

<p>UBS  analyst Joshua Spector   maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $67 to $71.</p>


CTVA

UBS Maintains Buy on Corteva, Raises Price Target to $71

<p>Susquehanna  analyst Biju Perincheril   maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Neutral and lowers the price target from $20 to $11.</p>


SEDG

Susquehanna Maintains Neutral on SolarEdge Technologies, Lowers Price Target to $11

<p>UBS  analyst Dan Brennan   maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Buy and raises the price target from $240 to $250.</p>


UBS Maintains Buy on Charles River, Raises Price Target to $250

<p>Susquehanna  analyst Christopher Rolland   maintains Power Integrations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWI#NASDAQ">POWI</a>) with a Positive and lowers the price target from $80 to $77.</p>


POWI

Susquehanna Maintains Positive on Power Integrations, Lowers Price Target to $77

Upwork Inc. 2024 Q3 - Results - Earnings Call Presentation

Upwork Inc. (UPWK) Q3 2024 Earnings Call Transcript

JMP Securities analyst Andrew Boone reiterated a Buy rating on Upwork (UPWK – Research Report) today and set a price target of $18.00. The company'...

JMP Securities Sticks to Their Buy Rating for Upwork (UPWK)

In a report released today, Marvin Fong from BTIG maintained a Buy rating on Upwork (UPWK – Research Report), with a price target of $16.00. The co...

BTIG Reaffirms Their Buy Rating on Upwork (UPWK)

Bernie McTernan, an analyst from Needham, reiterated the Buy rating on Upwork (UPWK – Research Report). The associated price target was raised to $...

Buy Rating Maintained Despite Lowered 2025 Projections and Cost-Cutting Initiatives

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Upwork (UPWK – Research Report), ZipRecruite...

Analysts Offer Insights on Industrial Goods Companies: Upwork (UPWK), ZipRecruiter (ZIP) and Ushio (OtherUHOIF)

Canaccord analyst Maria Ripps raised the firm's price target on Upwork (UPWK) to $18 from $15 and keeps a Buy rating on the shares. The firm said i...

Upwork price target raised to $18 from $15 at Canaccord

In a report released today, Rohit Kulkarni from Roth MKM maintained a Buy rating on Upwork (UPWK – Research Report), with a price target of $20.00....

Roth MKM Sticks to Their Buy Rating for Upwork (UPWK)

Roth MKM raised the firm's price target on Upwork (UPWK) to $20 from $13 and keeps a Buy rating on the shares. The company's Q4 EBITDA guide came c...

Upwork price target raised to $20 from $13 at Roth MKM

JMP Securities raised the firm's price target on Upwork (UPWK) to $18 from $14 and keeps an Outperform rating on the shares. Upwork reported strong...

Upwork price target raised to $18 from $14 at JMP Securities

UHOIF

UPWK

Press Releases

Beeline and Upwork Announce Strategic Partnership to Deliver Enhanced Hiring Efficiency and Centralized Workforce Management

Upwork Reports Second Quarter 2024 Financial Results

Upwork to Present at Goldman Sachs Communacopia + Technology Conference

Engine Capital Sends Letter to Upwork's Board of Directors Regarding Opportunities to Substantially Increase Shareholder Value

General

Upwork Confirms Receipt and Comments on Shareholder Letter

Upwork Study Finds Companies That Integrate Distributed Work, Flexible Talent Strategies, and Advanced Technology Achieve Better Financial Outcomes

Upwork to Report Third Quarter Financial Results on November 6, 2024

Upwork Expands AI Innovation and Unveils New Solutions for Better Work Outcomes with Upwork Updates Fall 2024 Release

Upwork Announces Organizational Changes to Drive Continued Profitable Growth and Provides Preliminary Third Quarter 2024 Results Above Financial Guidance

Comments

Upwork

Upwork (UPWK) Opciones

Upwork (NASDAQ:UPWK) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL